The companies will develop a robotic system to improve patient outcomes in complex hemorrhagic cases and time-sensitive ischemic strokes.
Stryker, Siemens Healthineers partner on neurovascular robot Read More »
Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate lacutamab and the AstraZeneca-partnered monalizumab.
Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’ Read More »
The New York-based provider said it’s cutting less than 2% of staff as it contends with rising expenses.
In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s Read More »
The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.
GOP bill extends telehealth flexibilities, sidesteps ACA subsidies Read More »
The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.
GOP bill extends telehealth flexibilities, sidesteps ACA subsidies Read More »
A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a pharma company must do. Experts say it’s time for the FDA to crack down.
FDA Takes Long Overdue Baby Step Toward Regulating Compounder Drug Ads Read More »
America’s primary care chassis is crumbling. How Medicare pays physicians is partially to blame. But expanding value-based payment arrangements could be the answer, experts say.
How to reform Medicare’s physician fee schedule to reprioritize primary care Read More »
The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron “underperformed” expectations in a previous readout, according to analysts at BMO Capital Markets.
Lilly Paints ‘Competitive Profile’ for Obesity Pill With Detailed Late-Stage Data Read More »
This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part of a $27 billion U.S. investment announced earlier this year.
Lilly to Bring Nearly 2,500 Jobs to Virginia With $5B Manufacturing Plant Read More »
